These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21347839)

  • 1. Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease.
    Cordellini MF; Piazzetta G; Pinto KC; Delattre AM; Matheussi F; Carolino RO; Szawka RE; Anselmo-Franci JA; Ferraz AC
    Neurochem Res; 2011 Jun; 36(6):955-61. PubMed ID: 21347839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle.
    Ferraz AC; Matheussi F; Szawka RE; Rizelio V; Delattre AM; Rigon P; Hermel Edo E; Xavier LL; Achaval M; Anselmo-Franci JA
    Neurochem Res; 2008 Jul; 33(7):1238-46. PubMed ID: 18259859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
    Quesada A; Micevych PE
    J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females.
    Murray HE; Pillai AV; McArthur SR; Razvi N; Datla KP; Dexter DT; Gillies GE
    Neuroscience; 2003; 116(1):213-22. PubMed ID: 12535954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
    Liu B; Dluzen DE
    Synapse; 2006 Oct; 60(5):354-61. PubMed ID: 16838362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice.
    Cui J; Zhao D; Xu M; Li Z; Qian J; Song N; Wang J; Xie J
    Sci Rep; 2024 Feb; 14(1):3721. PubMed ID: 38355892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
    Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
    Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
    Matsuura K; Makino H; Ogawa N
    Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
    Liu B; Dluzen DE
    Neuroendocrinology; 2006; 83(5-6):295-302. PubMed ID: 16926530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17β-Estradiol infusions into the dorsal striatum rapidly increase dorsal striatal dopamine release in vivo.
    Shams WM; Sanio C; Quinlan MG; Brake WG
    Neuroscience; 2016 Aug; 330():162-70. PubMed ID: 27256507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
    Ferraz AC; Xavier LL; Hernandes S; Sulzbach M; Viola GG; Anselmo-Franci JA; Achaval M; Da Cunha C
    Brain Res; 2003 Oct; 986(1-2):200-5. PubMed ID: 12965246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.